New Findings from University of Naples Federico II in the Area of Acute Coronary Syndrome Reported (Strike Early-strike Strong Lipid-lowering Strategy With Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors In Acute Coronary Syndrome...).

Předmět:	ACUTE coronary syndrome SUBTILISINS PROTEOLYTIC enzymes PROPROTEIN convertases MEDICAL sciences PRASUGREL
Zdroj:	Heart Disease Weekly; 7/1/2024, p535-535, 1p
Abstrakt:	A study conducted by researchers at the University of Naples Federico II in Italy investigated the effects of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in patients with acute coronary syndrome (ACS). The study included 771 ACS patients who received PCSK9i prescription during hospitalization or at discharge. The results showed that intensive and early lipid-lowering therapy using PCSK9i was safe and effective in reducing cardiovascular risk in ACS patients. The study highlights the potential benefits of this strategy in clinical practice. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu